Infectious Disease
-
Study shows glucocorticoids cut mortality in community acquired pneumonia in low-income settings
Anthony O. Etyang, MBChB, MMed, MSc, PhD, said recent data bolster the evidence that steroids may be useful for severe pneumonia in high-income settings as well.
-
Trials suggest RSV vaccine reduces hospitalization for cardiorespiratory conditions in older adults
Data from studies in the United States and Denmark add to the growing evidence that respiratory syncytial virus (RSV) vaccination is effective in older adults.
-
Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children
This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.
-
Data suggest pneumococcal vaccination is underused
Respiratory medicine expert Christina Thornton, MD, PhD, said recent real-world data demonstrate high rates of community-acquired pneumonia driven by serotypes targeted by vaccines.
-
Case discussions to address complexities of mediastinal lymphadenopathy diagnosis
Sebastian Kurz, MD, PhD, FCCP, will chair a Wednesday afternoon panel session that will guide attendees through imaging findings, differential diagnoses, and clinical decision-making in mediastinal lymphadenopathy.
-
Experts discuss advances in understanding, management of chronic cough
Sumera Ahmad, MBBS, discussed pharmacological innovations for chronic cough, including P2X3 antagonists, opiates, and neuromodulators.
-
90th anniversary sessions to reflect on past, present, and future of field
Nichole T. Tanner, MD, MSCR, FCCP, and five other CHEST experts will chair special sessions about 90 years of progress in mechanical ventilation, TB, lung cancer, diffuse lung disease, respiratory vaccines, and asthma.
-
Session to review latest science, recommendations for vaccines against respiratory infections
Charles Dela Cruz, MD, PhD, will chair a Sunday afternoon session on current practice recommendations for COVID-19, influenza, RSV, and pneumococcal vaccines.
-
Azelastine nasal spray shows promise in preventing SARS-CoV-2 infections
Researcher Robert Bals, MD, PhD, said this is a starting point, a signal of efficacy that warrants confirmation in larger, multicentric, phase 3 trials.
-
Session to outline strategies for emerging pathogen preparedness
Kevin Swiatek, DO, FCCP, will chair a session addressing obstacles to and opportunities for a comprehensive response to emerging pathogens in the United States.
